Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. WST
stocks logo

WST

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
795.31M
+6.21%
1.832
+0.64%
759.98M
+8.88%
1.646
+13.52%
815.62M
+6.41%
1.946
+5.76%
Estimates Revision
The market is revising Upward the revenue expectations for West Pharmaceutical Services, Inc. (WST) for FY2025, with the revenue forecasts being adjusted by 0.46% over the past three months. During the same period, the stock price has changed by 12.38%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.46%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+5.07%
In Past 3 Month
Stock Price
Go Up
up Image
+12.38%
In Past 3 Month
Wall Street analysts forecast WST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WST is 349.56 USD with a low forecast of 311.00 USD and a high forecast of 375.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
Wall Street analysts forecast WST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WST is 349.56 USD with a low forecast of 311.00 USD and a high forecast of 375.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
1 Hold
0 Sell
Strong Buy
Current: 281.770
sliders
Low
311.00
Averages
349.56
High
375.00
Current: 281.770
sliders
Low
311.00
Averages
349.56
High
375.00
TD Cowen
Brendan Smith
Buy
initiated
$350
2025-10-29
Reason
TD Cowen
Brendan Smith
Price Target
$350
2025-10-29
initiated
Buy
Reason
TD Cowen analyst Brendan Smith initiated coverage of West Pharmaceutical with a Buy rating and $350 price target. West sits at the nexus of multiple, sector-wide trends - including injectable biologics, GLP-1s and expanding regulatory demand - that have helped the company evolve from a supplier of standard drug delivery components towards high-value products with higher gross margins, the analyst tells investors. The mix shift to higher value products should sustainably grow revenue and margins long term, the analyst contends.
Barclays
Equal Weight
maintain
$275 -> $325
2025-10-27
Reason
Barclays
Price Target
$275 -> $325
2025-10-27
maintain
Equal Weight
Reason
Barclays raised the firm's price target on West Pharmaceutical to $325 from $275 and keeps an Equal Weight rating on the shares. The company reported a "solid beat across the board" and has a good setup into 2026, the analyst tells investors in a research note.
Evercore ISI
Daniel Markowitz
Tactical Outperform -> Outperform
downgrade
$390
2025-10-27
Reason
Evercore ISI
Daniel Markowitz
Price Target
$390
2025-10-27
downgrade
Tactical Outperform -> Outperform
Reason
Evercore ISI analyst Daniel Markowitz had a "Tactical Outperform" call on West Pharmaceutical heading into earnings, but is removing it from the firm's TAP list given that West reported earnings late last week. The firm has an Outperform rating and $390 price target on the shares.
UBS
Dan Leonard
Buy
maintain
$320 -> $355
2025-10-24
Reason
UBS
Dan Leonard
Price Target
$320 -> $355
2025-10-24
maintain
Buy
Reason
UBS analyst Dan Leonard raised the firm's price target on West Pharmaceutical to $355 from $320 and keeps a Buy rating on the shares.
BofA
Buy
upgrade
$310 -> $370
2025-10-24
Reason
BofA
Price Target
$310 -> $370
2025-10-24
upgrade
Buy
Reason
BofA raised the firm's price target on West Pharmaceutical to $370 from $310 and keeps a Buy rating on the shares after a "strong" Q3 report. The firm, which increased its EPS estimates by 5%-6%, cites growth drivers and normalizing market conditions heading into 2026 for its Buy rating.
Deutsche Bank
Justin Bowers
Buy
maintain
$305 -> $345
2025-10-24
Reason
Deutsche Bank
Justin Bowers
Price Target
$305 -> $345
2025-10-24
maintain
Buy
Reason
Deutsche Bank analyst Justin Bowers raised the firm's price target on West Pharmaceutical to $345 from $305 and keeps a Buy rating on the shares.
See All Ratings

Valuation Metrics

The current forward P/E ratio for West Pharmaceutical Services Inc (WST.N) is 38.11, compared to its 5-year average forward P/E of 42.59. For a more detailed relative valuation and DCF analysis to assess West Pharmaceutical Services Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
42.59
Current PE
38.11
Overvalued PE
49.96
Undervalued PE
35.21

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
28.04
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
32.99
Undervalued EV/EBITDA
23.08

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
8.02
Current PS
0.00
Overvalued PS
9.62
Undervalued PS
6.42
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 196.32% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

WST News & Events

Events Timeline

(ET)
2025-12-01
16:30:00
Morgan Stanley Initiates Coverage of West Pharmaceutical with $285 Price Target
select
2025-10-23 (ET)
2025-10-23
09:55:01
Significant Early Gainers in Liquid Options on October 23rd
select
2025-10-23
06:11:45
West Pharmaceutical Raises FY25 Adjusted EPS Forecast to $7.06-$7.11, Up from $6.65-$6.85
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-22Yahoo Finance
West Pharmaceutical Services (WST): Assessing Valuation Following Strong Q3 Results, Increased Guidance, and Positive Market Trends

  • Strong Quarterly Performance: West Pharmaceutical Services reported a 7.7% year-over-year increase in net sales for the third quarter, leading to a raised full-year guidance and a 5.2% jump in share price, although the stock remains down over 17% year-to-date.

  • Valuation and Growth Potential: The stock is currently trading at a price-to-earnings ratio of 39.7x, above industry averages, suggesting that the market may be pricing in significant future growth potential, with a fair value estimate of $350.77 indicating it is undervalued.

  • Future Opportunities and Risks: The company is expected to benefit from growth in GLP-1s and operational efficiencies from new automated lines, but ongoing restructuring and demand shifts could pose risks to these optimistic projections.

  • Investment Insights: The article encourages investors to explore high-potential stocks and highlights opportunities in dividend stocks, healthcare AI, and cryptocurrency, while emphasizing that the analysis is not financial advice.

[object Object]
Preview
6.5
11-18MarketWatch
These stocks have faced significant declines in 2025 but may rebound by up to 57% moving forward.

  • Current Market Status: The S&P 500 remains in a bull market, having risen 14.5% this year, despite some stock declines.

  • Stock Opportunities: Analysts have identified significantly declined stocks that are expected to rebound, focusing on projected growth rates for sales and earnings to avoid "value traps."

  • Market Performance: As of Friday, 57% of S&P 500 stocks were up for 2025, indicating a generally positive market sentiment.

  • Investment Strategy: The article emphasizes the importance of identifying potential growth stocks while being cautious of those that may not recover.

[object Object]
Preview
8.0
11-10NASDAQ.COM
Ex-Dividend Alert: West Pharmaceutical Services, Cohen & Steers Tax-Advantaged Preferred Securities, and Home BancShares

  • Upcoming Ex-Dividend Dates: On 11/12/25, West Pharmaceutical Services (WST), Cohen & Steers Tax-advantaged Preferred Securities (PTA), and Home BancShares Inc (HOMB) will trade ex-dividend, with respective dividends of $0.22, $0.134, and $0.21 scheduled for payment on 11/19/25, 11/28/25, and 12/3/25.

  • Expected Price Adjustments: Following the ex-dividend dates, WST shares are expected to open 0.08% lower, PTA by 0.67%, and HOMB by 0.76%, based on their recent stock prices.

  • Dividend Yield Estimates: The estimated annualized yields for the upcoming dividends are 0.32% for WST, 8.09% for PTA, and 3.06% for HOMB, indicating varying levels of return for investors.

  • Market Performance: In recent trading, WST shares are down about 1.6%, while PTA shares have increased by 0.1% and HOMB shares are up by 1.4%.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is West Pharmaceutical Services Inc (WST) stock price today?

The current price of WST is 281.77 USD — it has decreased -0.89 % in the last trading day.

arrow icon

What is West Pharmaceutical Services Inc (WST)'s business?

West Pharmaceutical Services, Inc. is a global manufacturer that is engaged in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. The Company operates in two segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers elastomers & primary containment, drug delivery devices, integrated solutions, and analytical lab services, primarily to biologic, generic, and pharmaceutical drug customers. The Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. This segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.

arrow icon

What is the price predicton of WST Stock?

Wall Street analysts forecast WST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WST is 349.56 USD with a low forecast of 311.00 USD and a high forecast of 375.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is West Pharmaceutical Services Inc (WST)'s revenue for the last quarter?

West Pharmaceutical Services Inc revenue for the last quarter amounts to 804.60M USD, increased 7.73 % YoY.

arrow icon

What is West Pharmaceutical Services Inc (WST)'s earnings per share (EPS) for the last quarter?

West Pharmaceutical Services Inc. EPS for the last quarter amounts to 1.93 USD, increased 4.32 % YoY.

arrow icon

What changes have occurred in the market's expectations for West Pharmaceutical Services Inc (WST)'s fundamentals?

The market is revising Upward the revenue expectations for West Pharmaceutical Services, Inc. (WST) for FY2025, with the revenue forecasts being adjusted by 0.46% over the past three months. During the same period, the stock price has changed by 12.38%.
arrow icon

How many employees does West Pharmaceutical Services Inc (WST). have?

West Pharmaceutical Services Inc (WST) has 10600 emplpoyees as of December 05 2025.

arrow icon

What is West Pharmaceutical Services Inc (WST) market cap?

Today WST has the market capitalization of 20.27B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free